Neuphoria Therapeutics (NEUP) Assets Average (2021 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Assets Average of $35.7 million for Q1 2026, up 46.08% year-over-year from $24.4 million in Q1 2025, and up 11.68% quarter-over-quarter from $32.0 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Assets Average (2021 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Assets Average for 6 consecutive years, with $35.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 46.08% year-over-year to $35.7 million; the TTM figure through Mar 2026 stood at $35.7 million (up 46.08% YoY), while the FY2025 annual figure was $28.1 million, changed 0.05% from the prior year.
- Assets Average climbed to $35.7 million in Q1 2026 per NEUP's latest filing, from $32.0 million in the prior quarter.
- Across five years, Assets Average topped out at $44.3 million in Q2 2022 and bottomed at $20.5 million in Q4 2024.
- Historically, Assets Average has averaged $30.8 million across 5 years, with a median of $29.7 million in 2025.
- Annual changes were most pronounced in 2022 — Assets Average jumped 108.38% — and 2023, when it decreased 14.73%.
- Neuphoria Therapeutics' Assets Average stood at $44.3 million in 2022, then fell by 14.73% to $37.8 million in 2023, then sank by 45.6% to $20.5 million in 2024, then soared by 55.63% to $32.0 million in 2025, then gained by 11.68% to $35.7 million in 2026.
- Business Quant data shows NEUP's Assets Average at $35.7 million in Q1 2026, $32.0 million in Q4 2025, and $28.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | 35.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.70 Mn |
| Dec 31, 2025 | 31.97 Mn |
| Sep 30, 2025 | 27.97 Mn |
| Jun 30, 2025 | 29.65 Mn |
| Mar 31, 2025 | 24.44 Mn |
| Dec 31, 2024 | 20.54 Mn |
| Sep 30, 2024 | 25.28 Mn |
| Jun 30, 2023 | 37.76 Mn |
| Jun 30, 2022 | 44.28 Mn |
| Jun 30, 2021 | 21.25 Mn |